Cover Image
市場調查報告書

吸煙成癮症:開發中產品分析

Smoking Addiction - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 363109
出版日期 內容資訊 英文 86 Pages
訂單完成後即時交付
價格
Back to Top
吸煙成癮症:開發中產品分析 Smoking Addiction - Pipeline Review, H1 2017
出版日期: 2017年06月13日 內容資訊: 英文 86 Pages
簡介

本報告提供吸煙成癮症治療藥的開發情形相關資訊,提供您各開發階段,藥物標的,作用機制,給藥途徑及分子類型別分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

吸煙成癮症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

吸煙成癮症:企業開發中的治療藥

吸煙成癮症:大學/機關研究中的治療藥

吸煙成癮症:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

吸煙成癮症:企業開發中的產品

吸煙成癮症:大學/機關研究中的產品

吸煙成癮症治療藥的開發企業

  • Aradigm Corporation
  • Arena Pharmaceuticals, Inc.
  • Astraea Therapeutics, LLC
  • Bioprojet SCR
  • Cerecor Inc.
  • CoMentis, Inc.
  • Embera NeuroTherapeutics, Inc.
  • Euthymics Bioscience, Inc.
  • Invion Limited
  • Johnson & Johnson
  • Marinus Pharmaceuticals, Inc.
  • NAL Pharmaceuticals Ltd.
  • Pfizer Inc.
  • Selecta Biosciences, Inc.
  • Zynerba Pharmaceuticals, Inc.

吸煙成癮症:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

吸煙成癮症:暫停中的計劃

吸煙成癮症:中止開發的產品

吸煙成癮症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9419IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Smoking Addiction - Pipeline Review, H1 2017, provides an overview of the Smoking Addiction (Central Nervous System) pipeline landscape.

In smoking addiction, people experience an uncontrollable dependence on cigarettes, which on stopping will cause severe mental, emotional or physical reactions. People addicted to smoking develop tolerance to nicotine. Nicotine acts on acetylcholine receptors causing the body to react to nicotine at these receptors in the same manner as it responds to acetylcholine. This leads to alterations in the activity and physiological functions of many brain systems. This causes structural and functional changes in the brains of smokers. Upon sudden nicotine withdrawal, the brain and other parts of the body get disturbed, leading to a condition called withdrawal syndrome. The body usually takes time to function in the absence of nicotine. The effects of smoking withdrawal stem from the lack of nicotine that can be overcome by nicotine replacement therapies such as the use of nicotine patch or nicotine chewing gum.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Smoking Addiction - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Smoking Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Smoking Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Smoking Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 5, 8, 6, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Smoking Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Smoking Addiction (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Smoking Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Smoking Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Smoking Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Smoking Addiction (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Smoking Addiction (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Smoking Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Smoking Addiction - Overview
    • Smoking Addiction - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Smoking Addiction - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Smoking Addiction - Companies Involved in Therapeutics Development
    • Aradigm Corp
    • Bionex Pharmaceuticals LLC
    • Bioprojet SCR
    • CoMentis Inc
    • Embera NeuroTherapeutics Inc
    • Invion Ltd
    • Jeil Pharmaceutical Co Ltd
    • Johnson & Johnson
    • Lotus Pharmaceutical Co Ltd
    • NAL Pharmaceuticals Ltd
    • Pfizer Inc
    • Rock Creek Pharmaceuticals, Inc.
    • Selecta Biosciences Inc
    • Sopharma AD
    • Zynerba Pharmaceuticals Inc
  • Smoking Addiction - Drug Profiles
    • (metyrapone + oxazepam) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AKR-214 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • amitifadine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Anatabine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AT-1001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BP-1.4979 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cytisine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GTS-21 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JLP-1603 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-39393406 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nadolol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NFL-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NIC-7DT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nicotine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nicotine bitartrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nicotine bitartrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-06413367 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SEL-068 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SEL-070 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize Alpha 4Beta 2 and Alpha 6Beta 2 Neuronal Nicotinic Receptor for Smoking Cessation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize Cannabinoid Receptor for Smoking Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Sodium Dependent Dopamine, Noradrenaline and Serotonin Transporters for Appetite Suppression and Smoking Cessation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize Neuronal Nicotinic Acetylcholine Receptor for Smoking Cessation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize CHRNA3 and CHRNB4 for Smoking Cessation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize CHRNB2 and CHRNA4 for Smoking Cessation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • URB-694 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Smoking Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Smoking Addiction - Dormant Projects
  • Smoking Addiction - Discontinued Products
  • Smoking Addiction - Product Development Milestones
    • Featured News & Press Releases
      • May 11, 2017: Selecta Biosciences Commences Dosing in Phase 1 Clinical Trial of Nicotine Vaccine for Smoking Cessation and Relapse Prevention
      • Mar 08, 2017: Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Cytisine Symposium at the Annual Society for Research in Nicotine and Tobacco Conference ("SRNT")
      • Oct 20, 2016: OWC Pharmaceutical Research Completes Development of Its Medical Cannabis Sublingual Tablet
      • Nov 17, 2015: Invion Phase 2 Smoking Cessation Data: Results of Ongoing Analysis
      • Oct 05, 2015: Invion Successfully Completes Phase 2 Study of INV102 to Aid Smoking Cessation
      • Jun 29, 2015: Invion completes dosing in key phase II clinical trial of oral INV102 in smoking cessation
      • Feb 02, 2015: Invion completes enrolment in its phase II trial of oral INV102 (nadolol) in smoking cessation
      • Jan 19, 2015: Invion Announces Positive Interim Data from Its Phase II Clinical Trial of Oral Inv102 (nadolol) in Smoking Cessation
      • Jul 01, 2014: Embera NeuroTherapeutics to Receive Grant for Clinical Trial Through New Crowd Funding Platform
      • Jan 29, 2014: FDA clears path for "Smoking Cessation" clinical trial of INV102 (nadolol)
      • Nov 11, 2013: Change to FDA reviewing division for smoking cessation clinical trial
      • Jul 22, 2013: INVION ANNOUNCES COMMENCEMENT OF PHASE II CHRONIC BRONCHITIS CLINICAL TRIAL
      • Dec 19, 2012: Invion Provides Update On INV102 Phase II Clinical Programs
      • Oct 17, 2012: Nabi Biopharma's Phase II Study Of NicVAX In Combination With Varenicline Does Not Meet Primary Endpoint
      • Mar 16, 2012: Embera And Collaborators Publish Paper In Psychopharmacology Supporting EMB-001 For Smoking Cessation
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Smoking Addiction, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Smoking Addiction - Pipeline by Aradigm Corp, H1 2017
  • Smoking Addiction - Pipeline by Bionex Pharmaceuticals LLC, H1 2017
  • Smoking Addiction - Pipeline by Bioprojet SCR, H1 2017
  • Smoking Addiction - Pipeline by CoMentis Inc, H1 2017
  • Smoking Addiction - Pipeline by Embera NeuroTherapeutics Inc, H1 2017
  • Smoking Addiction - Pipeline by Invion Ltd, H1 2017
  • Smoking Addiction - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017
  • Smoking Addiction - Pipeline by Johnson & Johnson, H1 2017
  • Smoking Addiction - Pipeline by Lotus Pharmaceutical Co Ltd, H1 2017
  • Smoking Addiction - Pipeline by NAL Pharmaceuticals Ltd, H1 2017
  • Smoking Addiction - Pipeline by Pfizer Inc, H1 2017
  • Smoking Addiction - Pipeline by Rock Creek Pharmaceuticals, Inc., H1 2017
  • Smoking Addiction - Pipeline by Selecta Biosciences Inc, H1 2017
  • Smoking Addiction - Pipeline by Sopharma AD, H1 2017
  • Smoking Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H1 2017
  • Smoking Addiction - Dormant Projects, H1 2017
  • Smoking Addiction - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Smoking Addiction, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top